iifl-logo

Marksans Pharma Ltd Share Price

224
(2.13%)
Apr 30, 2025|02:09:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open218.3
  • Day's High228.9
  • 52 Wk High358.7
  • Prev. Close219.32
  • Day's Low215.8
  • 52 Wk Low 130
  • Turnover (lac)3,655.49
  • P/E54.16
  • Face Value1
  • Book Value30.31
  • EPS4.05
  • Mkt. Cap (Cr.)10,150.87
  • Div. Yield0.27
View All Historical Data
No Records Found

Marksans Pharma Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

218.3

Prev. Close

219.32

Turnover(Lac.)

3,655.49

Day's High

228.9

Day's Low

215.8

52 Week's High

358.7

52 Week's Low

130

Book Value

30.31

Face Value

1

Mkt Cap (₹ Cr.)

10,150.87

P/E

54.16

EPS

4.05

Divi. Yield

0.27

Marksans Pharma Ltd Corporate Action

30 May 2024

12:00 AM

Dividend

Dividend Amount: 0.6

Record Date: 17 Sep, 2024

arrow

22 Jan 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

19 Aug 2024

12:00 AM

AGM

Announcement Date: 19 Aug, 2024

arrow

Marksans Pharma Ltd NEWS AND UPDATE

Marksans Pharma’s Relonchem Gets UK MHRA Approval for Baclofen 10 mg
21 Mar 2025|12:02 PM

Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets

Read More
Marksans Pharma gets USFDA approval for anti-allergy drug
22 Nov 2024|02:54 PM

The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Marksans Pharma Ltd SHAREHOLDING SNAPSHOT

30 Apr, 2025|02:35 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 43.87%

Foreign: 0.00%

Indian: 43.87%

Non-Promoter- 26.76%

Institutions: 26.76%

Non-Institutions: 29.36%

Custodian: 0.00%

Share Price

Marksans Pharma Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

45.32

45.32

134.03

40.93

Preference Capital

0

0

0

0

Reserves

1,177.39

1,066.01

650.64

558.79

Net Worth

1,222.71

1,111.33

784.67

599.72

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

599.54

433.41

294.66

215.83

yoy growth (%)

38.33

47.08

36.51

-39.73

Raw materials

-337.91

-243.03

-169.34

-112.37

As % of sales

56.36

56.07

57.47

52.06

Employee costs

-54.63

-48.5

-45.85

-39.77

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

124.32

52.72

16.65

11.94

Depreciation

-15.19

-11.64

-12.25

-15

Tax paid

-25.94

-14.82

-4.22

-0.4

Working capital

82.13

-10.16

7.89

46.78

Other operating items

View Cash Flow
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

38.33

47.08

36.51

-39.73

Op profit growth

59.06

96.13

48.84

-76.42

EBIT growth

116.05

146.78

47.96

-83.19

Net profit growth

159.55

205

7.64

-83.84

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

2,177.41

1,852.14

1,490.84

1,376.18

1,134.21

Excise Duty

0

0

0

0

0

Net Sales

2,177.41

1,852.14

1,490.84

1,376.18

1,134.21

Other Operating Income

0

0

0

0

0

Other Income

50.42

59.31

41.85

6.69

0.33

Marksans Pharma Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,805.5

137.464,33,031.981,181.050.755,985.3398.33

Divis Laboratories Ltd

DIVISLAB

6,108

78.271,62,251.745940.492,297513.62

Cipla Ltd

CIPLA

1,541.5

26.741,24,457.391,438.150.844,134.87360.72

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,322.7

61.631,12,419.764850.842,330222.38

Mankind Pharma Ltd

MANKIND

2,556.9

54.561,05,504.58416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Marksans Pharma Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

Mark Saldanha

Company Sec. & Compli. Officer

Harshavardhan Panigrahi

Non-Exec. & Independent Dir.

Seetharama Raju Buddharaju

Whole-time Director

Sandra Saldanha

Non-Exec. & Independent Dir.

Digant Mahesh Parikh

Whole-time Director

Varddhman Vikramaditya Jain

Non-Exec. & Independent Dir.

Abhinna Sundar Mohanty

Non Executive Director

Sunny Sharma

Independent Director

Shailaja Vardhan

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Companys research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited). The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015. The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA. The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20. The Company acquired the bus
Read More

Company FAQs

What is the Marksans Pharma Ltd share price today?

The Marksans Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹224 today.

What is the Market Cap of Marksans Pharma Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Marksans Pharma Ltd is ₹10150.87 Cr. as of 30 Apr ‘25

What is the PE and PB ratio of Marksans Pharma Ltd?

The PE and PB ratios of Marksans Pharma Ltd is 54.16 and 7.70 as of 30 Apr ‘25

What is the 52 Week High and Low of Marksans Pharma Ltd?

The 52-week high/low is the highest and lowest price at which a Marksans Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Marksans Pharma Ltd is ₹130 and ₹358.7 as of 30 Apr ‘25

What is the CAGR of Marksans Pharma Ltd?

Marksans Pharma Ltd's CAGR for 5 Years at 60.57%, 3 Years at 59.75%, 1 Year at 29.66%, 6 Month at -19.65%, 3 Month at -7.23% and 1 Month at -1.19%.

What is the shareholding pattern of Marksans Pharma Ltd?

The shareholding pattern of Marksans Pharma Ltd is as follows:
Promoters - 43.87 %
Institutions - 26.76 %
Public - 29.37 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.